About Medytox
Medytox is a company based in Seoul (South Korea) founded in 2000.. The company has 776 employees as of December 31, 2024. Medytox offers products and services including Meditoxin, Innotox, Neuramis, and Coretox. Medytox operates in a competitive market with competitors including Revance Therapeutics, Castle Creek Pharma, Dermavant, Sol-Gel Technologies and Bausch Health, among others.
- Headquarter Seoul, South Korea
- Employees 776 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Medy-Tox Inc.
-
Annual Revenue
$155.02 M (USD)3.39as on Dec 31, 2024
-
Net Profit
$11.49 M (USD)73.81as on Dec 31, 2024
-
EBITDA
$27.3 M (USD)23.31as on Dec 31, 2024
-
Latest Funding Round
-
Investors
-
Employee Count
776
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Medytox
Medytox is a publicly listed company on the KRX with ticker symbol 086900 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Medytox
Medytox offers a comprehensive portfolio of products and services, including Meditoxin, Innotox, Neuramis, and Coretox. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Botulinum toxin for aesthetic and therapeutic injections.
Liquid formulation for wrinkle treatment and muscle disorders.
Filler for facial volume enhancement and skin rejuvenation.
Toxin product for medical and cosmetic applications.
Funding Insights of Medytox
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Medytox
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Medytox
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Medytox Comparisons
Competitors of Medytox
Medytox operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Revance Therapeutics, Castle Creek Pharma, Dermavant, Sol-Gel Technologies and Bausch Health, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Neurotoxin products for aesthetic and therapeutic skin treatments are developed.
|
|
| domain | founded_year | HQ Location |
Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for inflammatory skin diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis.
|
|
| domain | founded_year | HQ Location |
Therapeutics for multiple diseases including dermatology and neurology are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics in aesthetics are developed, including botulinum toxin products.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Medytox
Frequently Asked Questions about Medytox
When was Medytox founded?
Medytox was founded in 2000.
Where is Medytox located?
Medytox is headquartered in Seoul, South Korea.
Who is the current CEO of Medytox?
Chung Hyun-ho is the current CEO of Medytox.
How many employees does Medytox have?
As of Dec 31, 2024, the latest employee count at Medytox is 776.
What is the annual revenue of Medytox?
Annual revenue of Medytox is $155.02M as on Dec 31, 2024.
What does Medytox do?
Medytox has developed a botulinum toxin for medical aesthetics therapeutic applications. The product, Meditoxin, a botulinum toxin type A marketed under trade names Neuronox, INNOTOX Coretox. These products are used for the treatments of muscle spasticity, foot deformities, Benign essential blepharospasm globular wrinkles. Also developed Hyaluronic Acid Filler (branded as Neuramis Potenfill) to the treatment of facial wrinkles and physical recovery. Also developed medical devices for tissue coagulation injecting applications. The company is also developing the pipeline of biodrugs, medical devices, synthetic drugs health supplements.
Who are the top competitors of Medytox?
Medytox's top competitors include Revance Therapeutics, Dermavant and Bausch Health.
What products or services does Medytox offer?
Medytox offers Meditoxin, Innotox, Neuramis, and Coretox.
Is Medytox publicly traded?
Yes, Medytox is publicly traded on KRX under the ticker symbol 086900.
What is Medytox's ticker symbol?
The ticker symbol of Medytox is 086900 on KRX.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.